TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28124478
Drug: Rifapentine (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifapentine (1200 mg daily)
Study: 25712967
Drug: 15-μg dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-μg dose of A/H5N1/Indonesia/05/05 (clade 2) vaccine
Study: 25712967
Drug: 90-μg dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90-μg dose of A/H5N1/Indonesia/05/05 (clade 2) vaccine
Study: 25712967
Drug: Low-dose priming
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose priming with mismatched pandemic influenza A(H5N1) vaccine
Study: 20192708
Drug: Hormone treatment
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone treatment with drospirenone 2 mg + estradiol emidrate 1 mg for 6 months
Study: 17854239
Drug: Longer time
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longer time to all-cause treatment discontinuation
Study: 15491558
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol (800 mcg)
Study: 9246650
Drug: Affect-management treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Affect-management treatment group (n = 17)
Study: 8297916
Drug: FeSO4 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: FeSO4 (60 or 120 mg Fe/d)
Study: 2436092
Drug: Amitriptyline (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (up to 150 mg nightly)
Study: 25323621
Drug: Aztreonam for
Normalized name: Aztreonam for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aztreonam for inhalation solution (AZLI)
Study: 19351876
Drug: valsartan treatment
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: valsartan treatment for 90 days
Study: 15526247
Drug: ACE inhibitor,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor, captopril
Study: 8366821
Drug: IVIG (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG (250 mg/Kg on the first and seventh day after admission)
Study: 26537570
Drug: Regular telephone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular telephone calls every 2 weeks and weekly text messages for 6 months (intervention group)
Study: 23010790
Drug: Antibiotics (amoxicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (amoxicillin with clavulanic acid) for 5 days
Study: 20086017
Drug: Chemokine receptor
Normalized name: Chemokine receptor antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemokine receptor 1 antagonist BX 471
Study: 16820546
Drug: Bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion SR (150 mg twice per day)
Study: 7745771
Drug: Accelerated recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated recombinant tissue‐type plasminogen activator (rt‐PA) plus IV heparin
Study: 7745771
Drug: Streptokinase plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase plus either subcutaneous or intravenous (IV) heparin
Study: 7745771
Drug: Combined streptokinase
Normalized name: streptokinase, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined streptokinase and rt‐PA plus IV heparin
Study: 2203214
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy (medical gymnastics)
Study: 7019293
Drug: Rinkel injection
Normalized name: Absidia capillata 0.076 g in 20 mL / ACROTHECIUM ROBUSTUM 0.077 g in 20 mL / MICROSPORUM AUDOUINII 0.077 g in 20 mL / MICROSPORUM CANIS 0.077 g in 20 mL / APIOSPORA MONTAGNEI 0.077 g in 20 mL / PHYCOMYCES BLAKESLEEANUS 0.077 g in 20 mL / SPOROTRICHUM PRUINOSUM 0.077 g in 20 mL / STACHYBOTRYS CHARTARUM 0.077 g in 20 mL / SYNCEPHALASTRUM RACEMOSUM 0.077 g in 20 mL / TETRACOCCOSPORIUM PAXIANUM 0.077 g in 20 mL / VERTICILLIUM ALBO-ATRUM 0.077 g in 20 mL / THERMOMYCES LANUGINOSUS 0.077 g in 20 mL / Trichosporon cutaneum 0.077 g in 20 mL SUBCUTANEOUS INJECTION, SOLUTION [RINKEL MOLD MIX C]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rinkel injection therapy (RIT)
Study: 30085324
Drug: Adalimumab (active
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (active treatment)
Study: 24905929
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) - GaAlAs diode laser [780 nm, 30 mW continuous wave (CW), 0.785 cm(2), 38.2 mW/cm(2)], applied for 90 sec per point, 5 times per week for 2 weeks, followed by 10 treatments every other day for 3 weeks (total of 20 treatments)
Study: 24905929
Drug: Placebo (sham)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sham) laser treatment
Study: 18793528
Drug: Cinacalcet administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinacalcet administered with the first major meal after dialysis
Study: 18793528
Drug: Cinacalcet administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinacalcet administered with food during the dialysis session
Study: 11797179
Drug: lamivudine-zidovudine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: lamivudine-zidovudine (150 mg/300 mg) combination tablet and one 300-mg abacavir tablet administered twice daily
Study: 8129119
Drug: Bupivacaine 0.5%
Normalized name: BUPivacaine 0.5% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.5% with adrenaline 5 micrograms.ml‐1 (dose 40 mg)
Study: 2628746
Drug: meat vegetable
Normalized name: Hydrogenated Vegetable Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: meat vegetable dinner fortified with iron‐2‐sulfate (3 mg iron per 100 kcal)
Study: 2628746
Drug: milk based
Normalized name: milk based formulas
Approvals — FDA: no, EMA: no, PMDA: no
Description: milk based rice cereal (MBRC) fortified with iron‐3‐pyrophosphate (3 mg iron per 100 kcal)
Study: 31000477
Drug: VRC01 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: VRC01 (40 mg/kg) intravenously every 3 weeks for up to 24 weeks during analytic interruption of ART
Study: 26487008
Drug: Glucose ingestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose ingestion (1.7 g/min)
Study: 26487008
Drug: Sucrose ingestion
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucrose ingestion (1.7 g/min)
Study: 18573809
Drug: Inhalation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation treatment through a face mask
Study: 16720496
Drug: Cytostatic drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytostatic drug treatment close to surgery
Study: 15587929
Drug: Teicoplanin (TEI)
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin (TEI) administered with three 10 mg/kg Q12h loading infusions, and maintenance with 10 mg/kg or 15 mg/kg Q24h
Study: 11412732
Drug: Intradural-epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradural-epidural analgesia (IEA) - 25 microgram of intradural fentanyl with 2.5 mg of isobaric bupivacaine with adrenalin, followed by 8 mL bolus of 0.125% bupivacaine at 8 ml/h
Study: 11412732
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural analgesia (CEA) - 8 ml of 0.25% bupivacaine with adrenalin, followed by perfusion of 0.125% bupivacaine and 1 microgram/ml of fentanyl at 8 ml/h
Study: 7705386
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg 17 beta-oestradiol
Study: 2651054
Drug: Chronic magnesium
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic magnesium supplementation (2 g/day)
Study: 22280901
Drug: Aged garlic
Normalized name: Garlic 600 MG Oral Tablet [KYOLIC AGED GARLIC EXTRACT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aged garlic extract (2.56 g/d)
Study: 20374102
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment based on TCM pattern diagnosis
Study: 15767619
Drug: L-thyroxine, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-thyroxine, 100 microg/d (standard treatment)
Study: 15767619
Drug: L-thyroxine, 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-thyroxine, 75 microg/d plus liothyronine, 5 microg/d (combination treatment)
Study: 15767619
Drug: L-thyroxine, 87.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-thyroxine, 87.5 microg/d plus liothyronine, 7.5 microg/d (add-on combination treatment)
Study: 10570752
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human interleukin-3 (rhIL-3) administered subcutaneously at a dose of 5 micrograms/kg once a day for 10 days starting from day 4 of chemotherapy
Study: 10570752
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human interleukin-3 (rhIL-3) administered subcutaneously at a dose of 10 micrograms/kg once a day for 10 days starting from day 4 of chemotherapy
Study: 10570752
Drug: Control observation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control observation period (no rhIL-3 administration)
Study: 2370107
Drug: Pnu-Imune (23-valent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pnu-Imune (23-valent pneumococcus vaccine)
Study: 517882
Drug: Delta-9-tetrahydrocannabinol (THC),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delta-9-tetrahydrocannabinol (THC), 15 mg orally three times a day
Study: 517882
Drug: Prochlorperazine, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prochlorperazine, 10 mg orally three times a day
Study: 9156374
Drug: Dichloroacetate (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dichloroacetate (50 mg/kg) administered via 30-minute intravenous infusion
Study: 8395087
Drug: Hyperfractionated radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperfractionated radiotherapy (1.3 Gy twice daily for five weeks, total dose 65 Gy)
Study: 8395087
Drug: Conventional radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional radiotherapy (2.0 Gy daily for six weeks, total dose 60 Gy)
Study: 2441166
Drug: Transdermal clonidine
Normalized name: clonidine Transdermal System
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal clonidine patches (2.5 mg)
Study: 16170291
Drug: Topical treatment
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment with DRNA 5 mg vaginal suppositories for 15 days monthly, reduced gradually thereafter
Study: 8772549
Drug: Acipimox (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox (250 mg orally at -270 min and 250 mg at -60 min)
Study: 8772549
Drug: Acipimox with
Normalized name: acipimox
DrugBank: Acipimox (DB09055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox with Pyridostigmine (120 mg orally at -60 min)
Study: 1728249
Drug: m-chlorophenylpiperazine (m-CPP;
Approvals — FDA: no, EMA: no, PMDA: no
Description: m-chlorophenylpiperazine (m-CPP; 0.5 mg/kg orally)
Study: 1728249
Drug: fenfluramine hydrochloride
Normalized name: fenfluramine hydrochloride
DrugBank: Fenfluramine (DB00574)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fenfluramine hydrochloride (60 mg orally)
Study: 30431004
Drug: Edoxaban 15
Normalized name: edoxaban 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban 15 mg daily for 1 week (n = 93)
Study: 30431004
Drug: Edoxaban 15
Normalized name: edoxaban 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban 15 mg daily for 2 weeks (n = 109)
Study: 15357156
Drug: IV administration
Normalized name: IV Administration Set
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV administration set changed on day 4 (n = 203)
Study: 15357156
Drug: IV administration
Normalized name: IV Administration Set
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV administration set not changed (n = 201)
Study: 9727728
Drug: SSRI (paroxetine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRI (paroxetine) + augmenting agent (pindolol)
Study: 8053578
Drug: ACEI therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEI therapy stopped the evening before surgery (either enalapril or captopril)
Study: 3197373
Drug: Adrenaline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline infusion (0.27 nmol (50 ng) min‐1 kg‐1)
Study: 26323043
Drug: Antidepressant medication
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant medication with clinical management
Study: 23599435
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg tabalumab
Study: 18665938
Drug: Amoxicillin 1000
Normalized name: amoxicillin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 1000 mg with clarithromycin 500 mg and omeprazole 20 mg twice daily for 2 weeks (BID group, n = 93)
Study: 18665938
Drug: Amoxicillin 500
Normalized name: amoxicillin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 500 mg four times daily with clarithromycin 500 mg and omeprazole 20 mg twice daily for 2 weeks (QID group, n = 93)
Study: 15962678
Drug: Colloids (Haemaccel)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloids (Haemaccel) 10 ml/Kg before positioning
Study: 10501745
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of nitric oxide (INO) at 1-40 ppm for up to 30 days or until an endpoint was reached.
Study: 10501745
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment with inhaled nitric oxide (INO)
Study: 10501745
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of nitric oxide (INO)
Study: 10501745
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment without inhaled nitric oxide (INO)
Study: 8951777
Drug: 40 mg/day
Normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/day aspirin
Study: 7074822
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (propylene and polyethylene glycol, saline)
Study: 23524525
Drug: Pioglitazone 15
Normalized name: pioglitazone 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 15 mg twice a day
Study: 23524525
Drug: Glibenclamide 5
Normalized name: glibenclamide 5 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide 5 mg twice a day
Study: 23524525
Drug: Rosuvastatin 5
Normalized name: rosuvastatin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 5 mg added after 6 months
Study: 21330267
Drug: Older age
Normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Older age and belief in treatment effectiveness
Study: 15691552
Drug: Topical 0.02%
Normalized name: tretinoin topical 0.02% topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.02% mitomycin C
Study: 15691552
Drug: Corticosteroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid treatment (fluorometholone sodium 2%)
Study: 10795802
Drug: Visual Manipulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visual Manipulation Test (VMT) administered to children
Study: 1676394
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide 0.25 mg (IB)
Study: 1676394
Drug: Terbutalin 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutalin 2.5 mg (TER)
Study: 1676394
Drug: Sequential inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential inhalation of IB after TER
Study: 1676394
Drug: Sequential inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential inhalation of TER after IB
Study: 1676394
Drug: Both agents
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both agents (IB and TER)
Study: 6605370
Drug: PABA ester‐oxybenzone
Approvals — FDA: no, EMA: no, PMDA: no
Description: PABA ester‐oxybenzone preparation
Study: 24512496
Drug: DHEA (130
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA (130 mg for 5 days)
Study: 22678971
Drug: Internet-based cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive-behavioral intervention, 45 minutes, twice weekly for 5 weeks
Study: 15918384
Drug: Hydroxyethyl starch
Normalized name: Hydroxyethyl starch
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyethyl starch 500 mL
Study: 15918384
Drug: Gelatine 500
Normalized name: Gelatine
DrugBank: Gelatin (DB11242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelatine 500 mL
Study: 12707718
Drug: Oral eniluracil
Normalized name: Eniluracil
DrugBank: Eniluracil (DB03516)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral eniluracil (EU) 20 mg plus LV 30 mg on days 1-3 with a single dose of 5-FU 15-29 mg/m2 on day 2
Study: 12707718
Drug: Leucovorin (LV)
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Leucovorin (LV) 30 mg on days 1-2 with a single dose of EU at least 1 h prior to 5-FU 29 mg/m2 on day 2 weekly for 3 of 4 weeks
Study: 12707718
Drug: 5-FU 2300
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU 2300 mg/m2 as a pharmacokinetic reference
Study: 10655927
Drug: Cisatracurium 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisatracurium 0.1 mg kg‐1
Study: 2060339
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of inhaled verapamil
Study: 2060339
Drug: Highest dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highest dose of verapamil tolerated (20 to 160 mg)
Study: 6339939
Drug: True plasmapheresis
Normalized name: HAEMO-PAK UNIT FOR PLASMAPHERESIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: True plasmapheresis therapy
Study: 6339939
Drug: Sham plasmapheresis
Normalized name: HAEMO-PAK UNIT FOR PLASMAPHERESIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham plasmapheresis therapy
Study: 30268162
Drug: Aloe Vera
Normalized name: ALOE VERA
DrugBank: Aloe vera leaf (DB13906)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aloe Vera gel applied twice a day on hip, sacrum, and heel
Study: 30268162
Drug: Placebo (gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (gel of water and starch)
Study: 26370072
Drug: Dental treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental treatment for dental caries
Study: 25249234
Drug: Ceylon cinnamon
Normalized name: Ceylon Cinnamon Plus Biotin And Chromium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceylon cinnamon hydro‐alcoholic extract (CCE) 1 g
Study: 17268082
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 (100 mg), riboflavin (10 mg), niacin (50 mg) along with tamoxifen (10 mg twice a day) for 45 days
Study: 17268082
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 (100 mg), riboflavin (10 mg), niacin (50 mg) along with tamoxifen (10 mg twice a day) for 90 days
Study: 17268082
Drug: Tamoxifen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen therapy alone for more than 1 year
Study: 16119478
Drug: Fluvoxamine (l
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (l allele)
Study: 12394789
Drug: Stavudine (d4T)
Normalized name: STAVUDINE (d4T)
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stavudine (d4T) monotherapy
Study: 7763068
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone treatment (Genotropin 30 IU/m2/week)
Study: 2279745
Drug: Alclometasone dipropionate
Normalized name: Alclometasone Dipropionate
DrugBank: Alclometasone (DB00240)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alclometasone dipropionate cream 0.1%
Study: 113096
Drug: Hexamethylmelamine at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexamethylmelamine at 6 mg/kg/day orally for 21 days every 4 weeks
Study: 113096
Drug: Hexamethylmelamine at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexamethylmelamine at 8 mg/kg/day orally for 21 days every 6 weeks
Study: 23669000
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of tranexamic acid
Study: 20668790
Drug: Experimental treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental treatment that enquires directly into childhood trauma and understands present interpersonal difficulties as a compulsion to repeat the traumatic past.
Study: 20668790
Drug: Experimental treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental treatment costs.
Study: 20668790
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment costs.
Study: 14640390
Drug: Prescription of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription of efavirenz to NNRTI-naive patients
Study: 14640390
Drug: Prescription of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription of lamivudine
Study: 14640390
Drug: Prescription of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription of abacavir to abacavir-naive patients
Study: 14640390
Drug: Prescription of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription of nelfinavir
Study: 10672626
Drug: Sibutramine 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine 25 mg
Study: 10672626
Drug: Sibutramine 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine 75 mg
Study: 10672626
Drug: d‐amphetamine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐amphetamine 20 mg
Study: 1386491
Drug: Candoxatril (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candoxatril (150 mg twice daily)
Study: 6654301
Drug: Etofenamate cream
Normalized name: etofenamate
DrugBank: Etofenamate (DB08984)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etofenamate cream
Study: 6654301
Drug: Control medication
Normalized name: zinc pyrithione Medicated Shampoo [Dial Dandruff Control]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control medication (salicylic acid ointment)